Rotigotine percutaneous absorption patch, and preparation and application thereof

Abstract

The invention belongs to the technical field of medicine, and relates to a rotigotine percutaneous absorption patch, and preparation and application thereof. The patch can obviously relieve a crystalseparation phenomenon of a rotigotine patch and provides good skin penetration delivery performance. The rotigotine percutaneous absorption patch consists of a back lining layer, a medicine loaded pressure-sensitive adhesive layer and an anti-bonding layer, wherein the medicine loaded pressure-sensitive adhesive layer comprises rotigotine free alkali or rotigotine organic acid ionic liquid, pressure-sensitive adhesives and a percutaneous absorption enhancing agent, wherein the weight of the rotigotine free alkali or rotigotine organic acid ionic liquid accounts for 2.0 to 20 weight percent ofthe total weight of the medicine loaded pressure-sensitive adhesive layer; the weight of the pressure-sensitive adhesives accounts for 77 to 90 weight percent of the total weight of the pressure-sensitive adhesive layer; and the consumption of the percutaneous absorption enhancing agent accounts for 0 to 10 weight percent of the total weight of the pressure-sensitive adhesive layer. In the rotigotine organic acid ionic liquid, a mol ratio of the rotigotine free alkali to different organic acids is 0.5:1-2:1. The rotigotine percutaneous absorption patch has the advantages that the accumulated penetration amount of rotigotine in 24h can reach 0.5mg / cm<2>. The preparation technology of the patch is simple; the stability of the patch is high; and the use is convenient.

Description

Technical field: [0001] The invention belongs to the technical field of medicine, and relates to a rotigotine percutaneous absorption patch and its preparation and application. The patch can significantly improve the crystallization phenomenon of the rotigotine patch and provide good skin penetration performance. Background technique: [0002] Parkinson's disease, also known as Parkinson's paralysis, is one of the most common central nervous system degenerative diseases in middle-aged and elderly people. It is a chronic central nervous system neurodegenerative disease caused by extrapyramidal system dysfunction. Typical symptoms include motor symptoms such as resting tremor, muscle stiffness, slowness of movement, abnormal posture and gait, and non-motor symptoms such as anxiety and depression, smell disturbance, sleep disturbance, numbness and pain. According to statistics, there are more than 10 million Parkinson's disease patients in the world, and nearly 3 million of th...

AI Technical Summary

Problems solved by technology

Poor compatibility between drug and matrix can lead to crystallization of drug molecules and inaccurate dosing

The main reason for the crystallization of the drug in the patch is the poor compatibility of the drug with the pressure-sensitive adhesive.

[0007] Therefore, need to seek a kind of preparation method, thereby overcome the problem of crystallization of rotigotine percutaneous absorption patch, make rotigotine percutaneous absorption patch be better applied to clinical

Images